Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178 is registered in ClinicalTrials.gov with Kevin Winthrop as lead sponsor.

NCT NCT03038178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03038178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease
Lead sponsor
Kevin Winthrop
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
December 31, 2019
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mycobacteria, atypical, mycobacterium infections, nontuberculous